Anke Biotechnology Advances Novel Drug Candidate as Clinical Trial Application Gains Regulatory Acceptance

Stock News

Sep 21

Anhui Anke Biotechnology (Group) Co., Ltd. (SZSE: 300009) has announced that its self-developed innovative drug, injection AK2405, has received acceptance of its clinical trial application from the National Medical Products Administration. The regulatory milestone marks a significant step forward in the company's oncology pipeline development.

Injection AK2405 is an antibody-drug conjugate (ADC) designed to target HER2, a well-established biomarker in cancer therapy. Preclinical studies have demonstrated that the candidate exhibits high specificity and potent anti-tumor activity, positioning it as a promising therapeutic option for patients with advanced malignancies.

The product is classified as a Class 1 therapeutic biological product, denoting its status as an innovative biologic, with the proposed indication covering advanced malignant solid tumors. This filing underscores the company's commitment to advancing cutting-edge treatments through its proprietary research and development efforts.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1150102229"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1150102229\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1150102229?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-21 16:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150102229","market":"sg","top_or_hot":-1,"title":"Anke Biotechnology Advances Novel Drug Candidate as Clinical Trial Application Gains Regulatory Acceptance","media":"Stock News","content":"<p><b>Anhui Anke Biotechnology (Group) Co., Ltd.</b> (<b>SZSE: 300009</b>) has announced that its self-developed innovative drug, injection AK2405, has received acceptance of its clinical trial application from the National Medical Products Administration. The regulatory milestone marks a significant step forward in the company's oncology pipeline development.<br><br>Injection AK2405 is an antibody-drug conjugate (ADC) designed to target HER2, a well-established biomarker in cancer therapy. Preclinical studies have demonstrated that the candidate exhibits high specificity and potent anti-tumor activity, positioning it as a promising therapeutic option for patients with advanced malignancies.<br><br>The product is classified as a Class 1 therapeutic biological product, denoting its status as an innovative biologic, with the proposed indication covering advanced malignant solid tumors. This filing underscores the company's commitment to advancing cutting-edge treatments through its proprietary research and development efforts.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Anke Biotechnology Advances Novel Drug Candidate as Clinical Trial Application Gains Regulatory Acceptance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnke Biotechnology Advances Novel Drug Candidate as Clinical Trial Application Gains Regulatory Acceptance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-21 16:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Anhui Anke Biotechnology (Group) Co., Ltd.</b> (<b>SZSE: 300009</b>) has announced that its self-developed innovative drug, injection AK2405, has received acceptance of its clinical trial application from the National Medical Products Administration. The regulatory milestone marks a significant step forward in the company's oncology pipeline development.<br><br>Injection AK2405 is an antibody-drug conjugate (ADC) designed to target HER2, a well-established biomarker in cancer therapy. Preclinical studies have demonstrated that the candidate exhibits high specificity and potent anti-tumor activity, positioning it as a promising therapeutic option for patients with advanced malignancies.<br><br>The product is classified as a Class 1 therapeutic biological product, denoting its status as an innovative biologic, with the proposed indication covering advanced malignant solid tumors. This filing underscores the company's commitment to advancing cutting-edge treatments through its proprietary research and development efforts.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"159992","symbol_name":"创新药","start_time":0,"source_url":"","article_id":"1150102229","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1150102229","pubTimestamp":1789977986,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Anhui Anke Biotechnology (Group) Co., Ltd. (SZSE: 300009) has announced that its self-developed innovative drug, injection AK2405, has received acceptance of its clinical trial application from the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","300009":"安科生物","06978":"永泰生物-B","BMED":"iShares Health Innovation Active ETF","BK0060":"抗癌","BK0070":"员工持股","MDTX":"Corgi MediaTek 2x Daily ETF","BK0042":"基因检测","IBBQ":"Invesco Nasdaq Biotechnology ETF","MEDX":"HORIZON KINETICS MEDICAL ETF","LNGR":"Global X Longevity Thematic ETF","BK0239":"医药制造","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","BK1161":"生物科技","PSYK":"PSYK ETF","BK1574":"生物医药B类股"},"translate_title":"临床试验申请获得监管机构批准，安科生物科技推进新型候选药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"300009":1,"LNGR":1,"MEDX":1,"PSYK":1,"06978":1,"MDTX":1,"BMED":1,"IBBJ":1,"IBBQ":1},"content_text":"Anhui Anke Biotechnology (Group) Co., Ltd. (SZSE: 300009) has announced that its self-developed innovative drug, injection AK2405, has received acceptance of its clinical trial application from the National Medical Products Administration. The regulatory milestone marks a significant step forward in the company's oncology pipeline development.Injection AK2405 is an antibody-drug conjugate (ADC) designed to target HER2, a well-established biomarker in cancer therapy. Preclinical studies have demonstrated that the candidate exhibits high specificity and potent anti-tumor activity, positioning it as a promising therapeutic option for patients with advanced malignancies.The product is classified as a Class 1 therapeutic biological product, denoting its status as an innovative biologic, with the proposed indication covering advanced malignant solid tumors. This filing underscores the company's commitment to advancing cutting-edge treatments through its proprietary research and development efforts.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}